Grant Sweep

Consolidated research funding across disease areas and research fields — federal, foundation, state & industry sources in one filterable place.

← Back to opportunities
OpenR21Clinical trial: Not allowed

Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)

National Institutes of Health (NIH) · NIH Institute/Center · PAR-25-229

Source: Grants.gov · View original posting ↗

Award
Amount not listed
Deadline
Sep 7, 2027
Letter of intent
Mechanism
R21
Duration
Expected awards
Funding cycle
Standard NIH dates
Open date
Nov 18, 2024
Total funding
Clinical trial
Not allowed
Higher educationGovernmentNonprofitSmall businessForeign entities

Funding context

16%of applications funded

Based on FY2024 NIH (all institutes) R21 applications (1,837 of 11,592 applications awarded).

Institute-specific data wasn’t available — showing the NIH-wide rate for this mechanism.

Payline: NIH discontinued percentile paylines for 2026 under its Unified Funding Strategy ↗ — scores are now weighed in context rather than against a fixed cutoff.

NIH-wide R21, all institutes.

Aggregate historical data by institute, mechanism, and fiscal year — context for planning, not a prediction for this opportunity. Source ↗

Research areas

Data & infrastructure

Auto-classified from the title and description (keyword-based) — may be imperfect.

Description

The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address increasingly larger data sets.

Data notes: award amount not published in the source feed; administering NIH institute could not be identified from the opportunity number.